This Scientific Program in the proposed CETR addresses the discovery and development of bacterially produced molecules that could become therapeutic agents to provide new antifungal and antibacterial agents to address the growing challenge to human health posed by resistant microbial pathogens. The emphasis on bacterially produced molecules is partly historical - most of our useful antifungal and antibacterial agents are, or were derived from, bacterially produced molecules - and partly ecological - the bacteria being investigated are symbionts on higher organisms and are known, or likely, producers of antimicrobials. This overall goal is based on three specific aims:
Specific Aim 1 : Explore symbiotic environmental niches and taxa for the production of novel compounds with antimicrobial activity against drug resistant target fungi and bacteria. This project will focus largely on Proteobacteria that have been isolated from symbiotic environments. Strains will be prioritized by phylogenetic novelty as measured by 16S sequencing.
Specific Aim 2 : Develop robust methods to identify novel natural products with antimicrobial activity against drug resistant target fungi and bacteria. Selected strains will be examined for biosynthetic potential through techniques such as culturing, co-culturing, genome sequencing, elicitors, and heterologous expression.
Specific Aim 3 : Identify combinations of symbiotic environments, taxa, and biological assays that most efficiently discovery safe and effective lead antimicrobials. Compounds with high activity levels in the screening cores, will be further examined. Production will be optimized, semi-synthetic derivatives will be prepared, and efforts to identify mechanism of action begun.
While the need for new drugs to combat fungal and bacterial infections that are increasingly resistant to current drugs is increasing, the rate of discovery of new drugs is decreasing. This proposal uses new approaches ranging from ecology to genome sequencing to discover new drugs from natural sources.
|Bratburd, Jennifer R; Keller, Caitlin; Vivas, Eugenio et al. (2018) Gut Microbial and Metabolic Responses to Salmonella enterica Serovar Typhimurium and Candida albicans. MBio 9:|
|Li, Hongjie; Sosa-Calvo, Jeffrey; Horn, Heidi A et al. (2018) Convergent evolution of complex structures for ant-bacterial defensive symbiosis in fungus-farming ants. Proc Natl Acad Sci U S A 115:10720-10725|
|Zhang, Fan; Barns, Kenneth; Hoffmann, F Michael et al. (2017) Thalassosamide, a Siderophore Discovered from the Marine-Derived Bacterium Thalassospira profundimaris. J Nat Prod 80:2551-2555|
|Adnani, Navid; Rajski, Scott R; Bugni, Tim S (2017) Symbiosis-inspired approaches to antibiotic discovery. Nat Prod Rep 34:784-814|
|Lawry, Stephanie M; Tebbets, Brad; Kean, Iain et al. (2017) Fludioxonil Induces Drk1, a Fungal Group III Hybrid Histidine Kinase, To Dephosphorylate Its Downstream Target, Ypd1. Antimicrob Agents Chemother 61:|
|Adnani, Navid; Braun, Doug R; McDonald, Bradon R et al. (2017) Draft Genome Sequence of Micromonospora sp. Strain WMMB235, a Marine Ascidian-Associated Bacterium. Genome Announc 5:|
|Matarrita-Carranza, Bernal; Moreira-Soto, Rolando D; Murillo-Cruz, Catalina et al. (2017) Evidence for Widespread Associations between Neotropical Hymenopteran Insects and Actinobacteria. Front Microbiol 8:2016|
|Adnani, Navid; Chevrette, Marc G; Adibhatla, Srikar N et al. (2017) Coculture of Marine Invertebrate-Associated Bacteria and Interdisciplinary Technologies Enable Biosynthesis and Discovery of a New Antibiotic, Keyicin. ACS Chem Biol 12:3093-3102|
|McDonald, Bradon R; Currie, Cameron R (2017) Lateral Gene Transfer Dynamics in the Ancient Bacterial Genus Streptomyces. MBio 8:|
|Chevrette, Marc G; Aicheler, Fabian; Kohlbacher, Oliver et al. (2017) SANDPUMA: ensemble predictions of nonribosomal peptide chemistry reveal biosynthetic diversity across Actinobacteria. Bioinformatics 33:3202-3210|
Showing the most recent 10 out of 23 publications